glp-1 medications mechanism of action of [25] Glucagon-Like Peptide-1 Based Therapies: A

While GLP-1 was originally FDA-approved for type 2 diabetes, its effectiveness in weight loss has led many healthcare providers to consider it for non-diabetic patients

Moreover, a counterintuitive reduction in N-terminal pro B-type natriuretic peptide concentrations on top of weight reduction has been shown in both STEP HFpEF trials, indicating potential direct cardiac effects of the therapies

Rules vary by state and federal guidance for controlled substances

Speaking to ETPharma, Leena Menghaney, a patient advocate and Lawyer, Public Health, Pharmaceuticals & Access, called the move as a much needed step citing that type-2 diabetes patients also need access to insulin-sparing regimens and these medicines that have been demonstrated to reduce mortality

There are a number of these medications currently available, some of which include: Semaglutide injection (Ozempic) Semaglutide injection (Wegovy) Semaglutide tablets (Rybelsus) Dulaglutide (Trulicity) Exenatide (Byetta) Exenatide extended-release (Bydureon) Liraglutide (Victoza) Lixisenatide (Adlyxin) Tirzepatide injection (Mounjaro) Source [1] Global GLP-1 receptor agonist market In 2024, the global GLP-1 receptor agonist market size was valued at an estimated USD 53.46 billion and is projected to reach USD 156.71 billion by 2030, with a Compound Annual Growth Rate (CAGR) of 17.46% between 2025 and 2030